ERBB2 and breast neoplasm: Most focus on STAT3 signalling is centred on pY705STAT3, the transcription-promoting form of the protein [54–56], which drives many adverse cancer features such as epithelial-mesenchymal transition in HER2-positive breast tumours [57].